Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2015

View Archived Issues

Opal Biosciences updates on development of antimicrobial platform

Takeda Pharmaceutical patents GPR6 modulators

Inception Sciences describes PPAR-alpha antagonists

Bristol-Myers Squibb discloses HIV integrase inhibitors

Bayer develops BRD4 inhibitors

Oncodrone given grant for development of lead candidate

Adocia and Lilly begin phase Ib study of ultra-rapid BioChaperone Lispro

Enrollment complete in second pivotal trial of Symbiomix Therapeutics' SYM-1219

Phase II trial of tarloxotinib bromide begins

ExIthera Pharmaceuticals reports FXIa and kallikrein inhibitors

Enumeral Biomedical gains access to ipilimumab patient samples

Alkeus initiates phase II trial of ALK-001 for Stargardt disease

Allele Biotechnology launches new nano-antibody research tools

FDA approves empagliflozin/metformin for type 2 diabetes

Phase III data show advantage of ambrisentan-tadalafil combination in PAH

Exelixis receives first regulatory approval of cobimetinib in Switzerland

ER opioid with abuse-deterrent features shows efficacy for CLBP

FDA approves Amgen's Repatha

ProMetic expands PBI-4050 metabolic syndrome trial after safety review

Takeda gains expanded access rights to Vero cell technology platform

Minerva Biotechnologies licenses Sendai virus technology from ID Pharma

AGTC achieves patient enrollment milestone in phase I/II trial in X-linked retinoschisis

AstraZeneca studies MEDI-4736 in combination therapy for head and neck cancer

Inhibitors of IRE1/XBP-1 pathway identified for antileukemia activity

Localized Drug Action soft drug approach reduces ROCK inhibitor side effects

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...